US
CA
NZ
UK
AU
IND
Last update at 2024-12-12T19:08:57.182766Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Axonics, Inc. (AXNX): Strong Growth and Global Momentum in 2024
Mon 14 Oct 24, 12:55 PMRon Baron's Strategic Moves in Q2 2024: A Closer Look at Tesla's Position Adjustment
Wed 14 Aug 24, 11:04 PMAxonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
Thu 01 Aug 24, 09:25 PMAxonics Reports Second Quarter 2024 Financial Results
Thu 01 Aug 24, 08:01 PM7 Robotics Stocks That Could Grow Your Wealth
Mon 22 Jul 24, 12:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -62.31600M | -79.28500M | -54.91400M | -79.93400M | -32.48200M |
| Minority interest | - | - | - | - | - |
| Net income | -59.69800M | -80.06700M | -54.91500M | -79.93500M | -32.48300M |
| Selling general administrative | 40.24M | 32.78M | 25.55M | 19.08M | 9.36M |
| Selling and marketing expenses | 156.02M | 105.79M | 66.13M | 48.67M | 3.72M |
| Gross profit | 197.66M | 115.72M | 67.09M | 7.33M | 0.35M |
| Reconciled depreciation | 11.72M | 7.24M | 1.74M | 1.19M | 0.95M |
| Ebit | -42.38500M | -67.39400M | -53.76000M | -80.59900M | -32.08500M |
| Ebitda | -27.86900M | -60.11300M | -52.99900M | -77.62500M | -31.13900M |
| Depreciation and amortization | 14.52M | 7.28M | 0.76M | 2.97M | 0.95M |
| Non operating income net other | 2.63M | -7.47700M | -1.15400M | - | - |
| Operating income | -42.38500M | -67.39400M | -53.76000M | -80.59900M | -32.13700M |
| Other operating expenses | 316.09M | 247.68M | 165.29M | 94.42M | 32.84M |
| Interest expense | 2.43M | 7.43M | 1.87M | 2.31M | 1.34M |
| Tax provision | -2.61800M | 0.78M | 0.00100M | 0.00100M | 0.00100M |
| Interest income | 5.13M | 0.04M | 0.76M | 2.97M | 1.00M |
| Net interest income | 2.70M | -7.38600M | -1.11300M | 0.67M | -0.34500M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | 22.56M | 4.41M | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -2.61800M | 0.78M | 0.00100M | 0.00100M | 0.00100M |
| Total revenue | 273.70M | 180.29M | 111.53M | 13.82M | 0.71M |
| Total operating expenses | 240.05M | 183.11M | 120.85M | 87.93M | 32.49M |
| Cost of revenue | 76.04M | 64.57M | 44.44M | 6.49M | 0.36M |
| Total other income expense net | -19.93100M | -11.89100M | -1.15400M | 0.67M | -0.34500M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -59.69800M | -80.06700M | -54.91500M | -79.93500M | -32.48300M |
| Net income applicable to common shares | -59.69800M | -80.06700M | -54.91500M | -79.93500M | -32.48300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 719.92M | 659.35M | 547.95M | 342.21M | 219.82M |
| Intangible assets | 81.38M | 86.25M | 106.47M | 0.20M | 0.31M |
| Earning assets | - | - | - | - | - |
| Other current assets | 9.28M | 7.28M | 6.45M | 5.43M | 4.47M |
| Total liab | 82.36M | 89.21M | 65.51M | 54.84M | 36.82M |
| Total stockholder equity | 637.56M | 570.14M | 482.44M | 287.37M | 183.00M |
| Deferred long term liab | - | 16.41M | 19.22M | - | - |
| Other current liab | 25.59M | 54.62M | 17.85M | 12.63M | 5.55M |
| Common stock | 0.00500M | 0.00500M | 0.00500M | 0.00400M | 0.00300M |
| Capital stock | 0.00500M | 0.00500M | 0.00500M | 0.00400M | 0.00300M |
| Retained earnings | -380.35200M | -374.26400M | -314.56600M | -234.49900M | -179.58400M |
| Other liab | - | 16.41M | 29.59M | - | - |
| Good will | 99.42M | 94.41M | 105.51M | - | - |
| Other assets | 0.00000M | 0.61M | 7.73M | 7.74M | 0.58M |
| Cash | 104.81M | 238.85M | 220.88M | 241.18M | 171.08M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 45.82M | 65.25M | 26.87M | 45.68M | 12.03M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -77.19400M | -229.72900M | -210.46000M | -209.63700M | -145.69400M |
| Short term debt | 1.78M | 1.56M | 1.37M | 22.39M | 0.60M |
| Short long term debt | - | 32.60M | - | 21.11M | - |
| Short long term debt total | 27.62M | 9.12M | 10.42M | 31.54M | 25.39M |
| Other stockholder equity | 1033.78M | 969.54M | 803.56M | 522.30M | 363.01M |
| Property plant equipment | - | 6.80M | 6.92M | 6.33M | 7.25M |
| Total current assets | 491.42M | 465.07M | 321.32M | 327.95M | 211.68M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 389.47M | 270.46M | 287.17M | 182.69M |
| Short term investments | 240.15M | 118.36M | - | 0.00000M | 12.59M |
| Net receivables | 57.24M | 44.82M | 29.04M | 18.27M | 7.88M |
| Long term debt | - | - | - | - | 20.34M |
| Inventory | 79.94M | 55.77M | 64.95M | 63.06M | 15.66M |
| Accounts payable | 18.45M | 9.07M | 7.65M | 10.66M | 5.88M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -15.86700M | -25.14700M | -6.56000M | -0.43100M | -0.42800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00500M | 0.00500M | 0.00400M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -374.26400M | -314.56600M | -234.49900M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.74M | 6.81M | 7.73M | 7.74M | 4.78M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 228.50M | 194.28M | 226.63M | 14.26M | 8.14M |
| Capital lease obligations | 27.62M | 9.12M | 10.42M | 10.43M | 5.05M |
| Long term debt total | - | - | - | - | 20.34M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -118.13100M | -143.00200M | 12.59M | 45.29M | -60.05000M |
| Change to liabilities | 5.61M | 1.32M | 11.54M | 2.45M | 1.82M |
| Total cashflows from investing activities | -120.35400M | -143.00200M | 9.65M | 45.29M | -60.05000M |
| Net borrowings | - | -26.22200M | -26.11600M | -26.11600M | 20.00M |
| Total cash from financing activities | 133.97M | 170.51M | 144.19M | 110.95M | 165.34M |
| Change to operating activities | 3.15M | 3.16M | 6.32M | 2.69M | -1.99300M |
| Net income | -59.69800M | -80.06700M | -54.91500M | -79.93500M | -32.48300M |
| Change in cash | 17.97M | -20.30300M | 70.10M | 72.78M | 73.91M |
| Begin period cash flow | 220.88M | 241.18M | 171.08M | 98.31M | 24.40M |
| End period cash flow | 238.85M | 220.88M | 241.18M | 171.08M | 98.31M |
| Total cash from operating activities | 3.19M | -47.30600M | -83.74200M | -83.45400M | -31.37000M |
| Issuance of capital stock | 128.50M | 201.25M | 149.50M | 117.59M | 158.10M |
| Depreciation | 11.72M | 9.13M | 1.74M | 1.19M | 0.95M |
| Other cashflows from investing activities | - | -140.74100M | - | 46.63M | -58.82200M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 8.42M | -1.10800M | -47.35300M | -11.98600M | -2.25500M |
| Change to account receivables | -15.96800M | -8.99800M | -10.78100M | -7.52700M | -0.42700M |
| Sale purchase of stock | 133.97M | 185.46M | -9.01300M | -7.14100M | -12.62300M |
| Other cashflows from financing activities | 5.47M | 70.38M | -5.31000M | -6.63500M | 39.97M |
| Change to netincome | 54.28M | 27.87M | 15.69M | 8.39M | 2.48M |
| Capital expenditures | 2.22M | 2.26M | 2.94M | 1.34M | 1.23M |
| Change receivables | -15.96800M | -8.99800M | -10.78100M | - | - |
| Cash flows other operating | -1.18200M | -0.44000M | -0.44300M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 16.80M | -19.79500M | 70.10M | - | - |
| Change in working capital | -2.93100M | -9.81100M | -47.03300M | -14.37800M | -2.85500M |
| Stock based compensation | 32.02M | 25.16M | 15.10M | 8.72M | 0.61M |
| Other non cash items | 22.27M | 7.70M | 0.94M | 0.87M | 2.16M |
| Free cash flow | 0.97M | -49.56700M | -86.68000M | -84.79300M | -32.59800M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AXNX Axonics Modulation Technologies Inc |
- -% | - | - | 106.38 | 8.40 | 5.46 | 7.68 | 381.08 |
| ABT Abbott Laboratories |
-0.58 0.43% | 133.43 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-0.19 0.05% | 376.93 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-1.2 1.36% | 86.72 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
0.57 0.56% | 102.06 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation.
26 Technology Drive, Irvine, CA, United States, 92618
| Name | Title | Year Born |
|---|---|---|
| Mr. Raymond W. Cohen | CEO & Director | 1959 |
| Mr. Danny L. Dearen | Pres & CFO | 1963 |
| Mr. Rinda K. Sama | Chief Operating Officer | 1980 |
| Dr. John Woock Ph.D. | Exec. VP, Chief Marketing & Strategy Officer | 1984 |
| Mr. Alfred J. Ford Jr. | Chief Commercial Officer | 1971 |
| Mr. Guangqiang Jiang Ph.D. | Chief Technology Officer | 1974 |
| Mr. Neil Bhalodkar | VP of Investor Relations | NA |
| Mr. Aaron Pettit | Gen. Counsel & Chief Compliance Officer | NA |
| Mr. Michael V. Williamson Esq., J.D. | Sr. VP, Gen. & IP Counsel | 1972 |
| Dr. Karen L. Noblett M.A.S., M.D. | Chief Medical Officer | 1964 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...